Pharmacogenetics of disease-modifying therapies in multiple sclerosis: current evidence and emerging markers

Background Multiple sclerosis (MS) is a chronic, immune-mediated neurological disorder for which a variety of disease-modifying therapies (DMTs) with distinct mechanisms of action are now available. However, interindividual variability in drug response remains a significant clinical challenge. Objectives This narrative review aims to provide a comprehensive synthesis of the current evidence on pharmacogenetic markers associated with MS treatment response and toxicity, incorporating recent pharmacogenomic literature. Methods Based on data from the ClinPGx curated database and recent pharmacogenomic literature, pharmacogenetic variants associated with altered drug response were identified and categorized by phenotype and level of evidence. Results CYP2C9 haplotypes represent the only pharmacogenetic marker with regulatory actionability, guiding siponimod dosing. Recent larger studies identified MAP3K1 (rs2053696) as a genome-wide significant predictor of glatiramer acetate response, and HLA-A*03:01 as a clinically relevant marker enabling personalized choice between glatiramer acetate and interferon-β. For interferon-β, HLA haplotypes predict formulation-specific immunogenicity with high accuracy, while SLC9A9 represents a validated efficacy predictor. For anti-CD20 therapies, FCGR3A V158F (rs396991) is emerging as a class-level pharmacogenetic determinant of B-cell depletion. Conclusions Pharmacogenetics holds real promise for personalizing DMT selection in MS. Future integration of pharmacogenetic testing into clinical practice, supported by larger and more diverse cohorts, could support more effective and safer treatment strategies for individuals with MS.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-18
DOI
https://doi.org/10.3389/fimmu.2026.2006956
Primary Topic
Multiple Sclerosis Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pharmacogenetics of disease-modifying therapies in multiple sclerosis: current evidence and emerging markers

Enrico Zoroddu, Daiana Bezzini, Lorena Lorefice, Matteo Floris et al.
1 links
Frontiers in Immunology
Multiple Sclerosis Research Studies
article

Pharmacogenetics of disease-modifying therapies in multiple sclerosis: current evidence and emerging markers

Enrico Zoroddu, Daiana Bezzini, Lorena Lorefice, Matteo Floris, Maria Laura Idda, Giuseppe Fenu, Soumaya Mourou
article en

Abstract

Background Multiple sclerosis (MS) is a chronic, immune-mediated neurological disorder for which a variety of disease-modifying therapies (DMTs) with distinct mechanisms of action are now available. However, interindividual variability in drug response remains a significant clinical challenge. Objectives This narrative review aims to provide a comprehensive synthesis of the current evidence on pharmacogenetic markers associated with MS treatment response and toxicity, incorporating recent pharmacogenomic literature. Methods Based on data from the ClinPGx curated database and recent pharmacogenomic literature, pharmacogenetic variants associated with altered drug response were identified and categorized by phenotype and level of evidence. Results CYP2C9 haplotypes represent the only pharmacogenetic marker with regulatory actionability, guiding siponimod dosing. Recent larger studies identified MAP3K1 (rs2053696) as a genome-wide significant predictor of glatiramer acetate response, and HLA-A*03:01 as a clinically relevant marker enabling personalized choice between glatiramer acetate and interferon-β. For interferon-β, HLA haplotypes predict formulation-specific immunogenicity with high accuracy, while SLC9A9 represents a validated efficacy predictor. For anti-CD20 therapies, FCGR3A V158F (rs396991) is emerging as a class-level pharmacogenetic determinant of B-cell depletion. Conclusions Pharmacogenetics holds real promise for personalizing DMT selection in MS. Future integration of pharmacogenetic testing into clinical practice, supported by larger and more diverse cohorts, could support more effective and safer treatment strategies for individuals with MS.

Frontiers in ImmunologyVol. 17
University of Siena (IT), University of Sassari (IT), University of Cagliari (IT), ATS Sardegna (Italy) (IT), Azienda Ospedaliera G. Brotzu (IT)
Good health and well-being
Multiple Sclerosis Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon